<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04396990</url>
  </required_header>
  <id_info>
    <org_study_id>The RESTORE Study</org_study_id>
    <nct_id>NCT04396990</nct_id>
  </id_info>
  <brief_title>The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study</brief_title>
  <official_title>A Randomized, Controlled, Masked (Reading Center) Prospective Study of the Effectiveness and Safety of the Ocular Therapeutix Dextenza (Dexamethasone Ophthalmic Insert) 0.4 mg for the Treatment of Post-operative Inflammation and Pain in Patients Who Have Undergone PhotoREfractive Keratectomy (PRK)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vance Thompson Vision</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vance Thompson Vision</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine patient preference and treatment outcomes with an intracanalicular dexamethasone
      (0.4mg) insert compared to standard steroid drop regimen in the contralateral eye following
      bilateral PRK surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective Open-label Interventional Study Randomized, self-controlled design in which one
      eye (Group A) receives Dextenza and the second eye (Group B) receives prednisolone acetate 1%
      QID 1 week, BID 1 week following bilateral PRK surgery. All eyes will receive topical
      moxifloxacin QID for one week. Moxifloxacin in used post-op regardless of the research.
      Post-operative evaluations to be performed on Day 3 and Day 4, Month 1, and Month 3. Phone
      call survey to be performed on Week 2.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient preference</measure>
    <time_frame>Through Month 1 (Day 28 +/- 3 days)</time_frame>
    <description>As measured by adapted COMTOL survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of eyes epithelialized at Day 3 and Day 4.</measure>
    <time_frame>Post-Operative Day 3 and 4:</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean pain score per eye (Group A vs. Group B)</measure>
    <time_frame>Day 3, Day 4, Week 2 (collected via telephone survey), and Month 1</time_frame>
    <description>measured by the Numerical Rating Scale (NRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference</measure>
    <time_frame>Pre-op Visit and Month 1.</time_frame>
    <description>measured by a modified SPEED questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and grade of post-operative corneal haze</measure>
    <time_frame>Pre-op Visit, Month 1, and Month 3.</time_frame>
    <description>measured by Heidelberg Anterior Segment OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative corneal staining score</measure>
    <time_frame>Day 3, Day 4, Month 1, and Month 3.</time_frame>
    <description>measured by the National Eye Institute (NEI) grading system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected visual acuity</measure>
    <time_frame>Month 1 and Month 3.</time_frame>
    <description>measured by ETDRS chart at 4m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manifest Refraction Spherical Equivalent</measure>
    <time_frame>1 and Month 3</time_frame>
    <description>measured by the Optometrist</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractive Surgery</condition>
  <arm_group>
    <arm_group_label>Group A Dextenza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Topical Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4Mg Ophthalmic Insert</intervention_name>
    <description>The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.</description>
    <arm_group_label>Group A Dextenza</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Prednisolone</intervention_name>
    <description>Standard of care topical drop treatment</description>
    <arm_group_label>Group B Topical Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any adult patient who is planned to undergo bilateral PRK surgery.

          -  Willing and able to comply with clinic visits and study related procedures

          -  Willing and able to sign the informed consent form

        Exclusion Criteria:

          -  Patients under the age of 18.

          -  Patients who are pregnant (must be ruled out in women of child-bearing age with
             pregnancy test).

          -  Active infectious ocular or systemic disease.

          -  Patients with active infectious ocular or extraocular disease.

          -  Patients actively treated with local or systemic immunosuppression including systemic
             corticosteroids.

          -  Patients with known hypersensitivity to Dexamethasone.

          -  Patients with severe disease that warrants critical attention, deemed unsafe for the
             study by the investigator.

          -  Patients with a history of ocular inflammation or macular edema.

          -  Patients with allergy or inability to receive intracameral antibiotic.

          -  Patients on systemic non-steroidal anti-inflammatory drugs (NSAID) greater than 1,200
             mg/day

          -  Patients with a corticosteroid implant (i.e. Ozurdex).

          -  Patient with corneal pathology which pre-disposes them to unsatisfactory outcomes.

          -  Patients who do not have 20/20 snellen visual acuity potential pre-operatively.

          -  MRSE greater than 6 diopters.

          -  Greater than 2 diopters anisometropia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keeley Puls</last_name>
    <phone>605-371-7075</phone>
    <email>keeley.puls@vancethompsonvision.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Dunne</last_name>
    <phone>605-361-3937</phone>
    <email>kristin.dunne@vancethompsonvision.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keeley Puls</last_name>
      <phone>605-371-7075</phone>
      <email>keeley.puls@vancethompsonvision.com</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Dunne</last_name>
      <phone>6053613937</phone>
      <email>kristin.dunne@vancethompsonvision.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vance Thompson Vision</investigator_affiliation>
    <investigator_full_name>John Berdahl, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

